- Home
- THAR vs EDSA Comparison
THAR vs EDSA Comparison
Compare THAR & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- EDSA
- Stock Information
- Founded
- THAR 2017
- EDSA 2015
- Country
- THAR United States
- EDSA Canada
- Employees
- THAR N/A
- EDSA N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- EDSA Health Care
- Exchange
- THAR Nasdaq
- EDSA Nasdaq
- Market Cap
- THAR 16.8M
- EDSA 18.6M
- IPO Year
- THAR 2022
- EDSA N/A
- Fundamental
- Price
- THAR $3.16
- EDSA N/A
- Analyst Decision
- THAR Strong Buy
- EDSA Strong Buy
- Analyst Count
- THAR 1
- EDSA 2
- Target Price
- THAR $17.00
- EDSA $13.00
- AVG Volume (30 Days)
- THAR 556.4K
- EDSA 135.8K
- Earning Date
- THAR 11-06-2025
- EDSA 08-08-2025
- Dividend Yield
- THAR N/A
- EDSA N/A
- EPS Growth
- THAR N/A
- EDSA N/A
- EPS
- THAR N/A
- EDSA N/A
- Revenue
- THAR N/A
- EDSA N/A
- Revenue This Year
- THAR N/A
- EDSA N/A
- Revenue Next Year
- THAR N/A
- EDSA N/A
- P/E Ratio
- THAR N/A
- EDSA N/A
- Revenue Growth
- THAR N/A
- EDSA N/A
- 52 Week Low
- THAR $0.95
- EDSA $1.55
- 52 Week High
- THAR $9.08
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- THAR 51.38
- EDSA 51.07
- Support Level
- THAR $2.79
- EDSA $2.42
- Resistance Level
- THAR $3.52
- EDSA $2.90
- Average True Range (ATR)
- THAR 0.25
- EDSA 0.22
- MACD
- THAR 0.02
- EDSA -0.02
- Stochastic Oscillator
- THAR 51.02
- EDSA 39.70
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.